TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris

This clinical trial demonstrates that the TYK2 inhibitor deucravacitinib significantly improves clinical outcomes and resolves interferon-driven inflammation in Lichen Planopilaris by suppressing inflammatory circuits, reducing CD8+ T cell activity, and attenuating fibroblast signaling.

The Gist

Imagine your scalp is a bustling city. In a healthy city, the buildings (hair follicles) are strong, the streets are clean, and the security guards (immune cells) only show up when there's a real emergency.

The Problem: The False Alarm
In a condition called Lichen Planopilaris (LPP), the city's security system goes haywire. It starts screaming "Intruder!" when there is no intruder. This false alarm triggers a massive, angry mob of immune cells that doesn't just attack the "invader"—it starts tearing down the buildings (hair follicles) and replacing them with concrete (scar tissue). Once the concrete sets, the hair is gone forever.

For years, doctors have tried to calm this angry mob with various tools, but often the noise continues, and the city keeps getting destroyed.

The New Solution: The "Silencer" Button
This study tested a new, very specific tool: a pill called Deucravacitinib. Think of this pill not as a sledgehammer that knocks out the whole immune system, but as a specialized noise-canceling headphone for a specific type of alarm.

The researchers discovered that the "screaming" in LPP is driven by a specific signal called Type I Interferon. It's like a specific radio frequency that tells the immune cells to attack. Deucravacitinib is designed to tune into that specific frequency and mute it, without shutting down the entire city's security.

What Happened in the Study?
The researchers gave this "noise-canceling" pill to 10 people with severe, stubborn LPP for 24 weeks. Here is what they found:

1. The City Calmed Down: In 8 out of 10 patients, the inflammation stopped. The redness and scaling disappeared, and the "concrete" (scarring) stopped spreading. It was like turning down the volume on a deafening siren until the city could finally breathe.
2. The "Construction Crew" Stopped: Inside the scalp, they found a specific type of cell (a fibroblast) that was acting like an overzealous construction crew, pouring concrete everywhere. After the treatment, this crew slowed down significantly.
3. The "Angry Mob" Dispersed: They also found a specific group of immune cells (CD8+ T-cells) that were acting like a riot squad. The treatment told these cells to stand down and stop attacking the hair follicles.
4. People Felt Better: Beyond just the hair, the patients reported feeling much less itchy and much less stressed about their appearance. Their quality of life improved dramatically.

The Big Takeaway
This study is like finding the master key for a very stubborn lock. For a long time, doctors didn't know exactly which "lock" was stuck in LPP. This research shows that the lock is a specific chemical signal (Interferon) that can be turned off with a targeted pill.

Even more exciting? When some patients stopped taking the pill after 24 weeks, the improvement lasted for a while. It suggests the treatment didn't just temporarily sedate the immune system; it actually helped the city "reset" its own alarm system.

In Short:
This paper proves that a targeted pill can stop the immune system from mistakenly destroying hair follicles in LPP. It turns off the specific "false alarm" causing the damage, stops the scarring, and gives patients their confidence back. It's a major step forward in treating a disease that previously had very few good options.

Technical Summary

1. Problem Statement

Lichen Planopilaris (LPP) is a chronic, lymphocyte-mediated scarring alopecia characterized by progressive follicular destruction, perifollicular inflammation, and irreversible fibrosis.

• Clinical Challenge: There are currently no FDA-approved therapies for LPP. Conventional treatments (e.g., corticosteroids, hydroxychloroquine, mycophenolate mofetil) often yield mixed or poor responses, particularly in refractory cases.
• Pathogenic Gap: While the role of Type II Interferon (IFN) and Th1 responses is established in cutaneous lichen planus (LP), the specific molecular drivers of LPP, particularly the interplay between immune activation and the fibrotic scarring process, remain poorly understood. Previous studies suggest a potential role for Th17 cells and Type I IFN, but targeted therapeutic strategies are lacking.

2. Methodology

The study was a multi-center, exploratory, open-label, single-arm Phase II clinical trial (NCT-06091956) conducted at Mayo Clinic.

• Cohort: 11 patients with biopsy-proven LPP were enrolled; 10 patients with follow-up data were included in the analysis. The cohort consisted of treatment-refractory patients (100% failed topical steroids; 80% failed systemic treatments).
• Intervention: Patients received deucravacitinib (a selective oral TYK2 inhibitor) at 6 mg twice daily (BID) for 24 weeks.
• Clinical Assessments:
  • Primary Endpoint: Physician Global Assessment (PGA) at Week 24 (Response defined as PGA 0–3 with ≥50% reduction).
  • Secondary Endpoints: Lichen Planopilaris Activity Index (LPPAI), Skindex-16 (Quality of Life), DLQI, and pruritus scales (NRS, VAS).
  • Follow-up: Assessments continued to Week 28 (4 weeks post-treatment discontinuation) to evaluate durability.
• Molecular Profiling:
  • Bulk RNA-Seq: Performed on paired lesional scalp biopsies (Baseline vs. Week 4) and compared against healthy controls.
  • Single-Cell RNA-Seq (scRNA-seq): Performed on baseline and Week 4 biopsies from 8 responders to characterize cellular heterogeneity and cell-cell communication.
  • Analysis: Differential expression analysis (DESeq2), Gene Ontology enrichment, and CellChat analysis for ligand-receptor interactions.

3. Key Contributions

This study provides the first clinical and mechanistic evidence for the efficacy of selective TYK2 inhibition in LPP. Its primary contributions include:

1. Clinical Validation: Demonstrating that deucravacitinib induces significant clinical improvement in refractory LPP.
2. Transcriptomic Characterization: Defining the baseline molecular signature of LPP as an Interferon (IFN)-enriched inflammatory state coupled with extracellular matrix (ECM) remodeling.
3. Cellular Mechanism Elucidation: Identifying specific pathogenic cell populations (CD8+GZMK+ T cells and CCL19+ fibroblasts) and their response to therapy.
4. Therapeutic Insight: Establishing that selective TYK2 inhibition effectively suppresses Type I IFN signaling and disrupts the immune-fibrotic crosstalk driving scarring.

4. Key Results

A. Clinical Efficacy

• Response Rates: At Week 24, 88.9% (8/9) of patients were treatment responders (PGA 0–3).
  • 55.6% achieved "Marked Improvement" (PGA 2).
  • 33.3% achieved "Moderate Improvement" (PGA 3).
• Statistical Significance:
  • LPPAI: Mean score decreased from 3.8 to 1.5 ($p=0.002$).
  • Skindex-16: Mean score improved by 21.0 points ($p=0.014$), driven primarily by the Emotional subscore ($p=0.010$).
  • PGA: 88.9% of patients showed improvement ($p=0.008$).
• Durability: Clinical responses were sustained in 77.8% of patients at Week 28 (4 weeks off-therapy), suggesting durable disease modulation.
• Safety: The drug was well-tolerated. The most common adverse event was acne (69.2% of patients), which was mild. No serious treatment-emergent adverse events (TEAEs) occurred.

B. Molecular and Transcriptomic Findings

• Baseline Signature: Untreated LPP lesions showed massive upregulation of Type I IFN-stimulated genes (e.g., MX1, OAS2, IFI27) and chemokines (CXCL9, CXCL13, CCL19). Pathways related to inflammation, immune activation, and ECM remodeling/fibrosis (e.g., COL1A1, MMP1, MMP9) were significantly upregulated, while metabolic processes were downregulated.
• Treatment Effect: After 4 weeks of deucravacitinib, the transcriptomic profile shifted toward normalization:
  • Downregulation of viral response, immune activation, and inflammatory pathways.
  • Upregulation of cellular metabolic pathways.
  • Restoration of PPARG expression (a gene whose deletion causes scarring alopecia in mice).

C. Single-Cell Insights

• Keratinocytes: Basal keratinocytes showed reduced cytokine and IFN signaling post-treatment.
• T-Cells:
  • Untreated LPP was enriched with CD8+GZMK+ and KLF2+ T cells.
  • Unlike classic LP (driven by CXCL13+ T cells), LPP lacked CD8+CXCL13+ cells.
  • Treatment led to downregulation of T-cell receptor signaling, antiviral pathways, and IL-17 signaling in CD8+GZMK+ T cells.
• Fibroblasts:
  • CCL19+ fibroblasts were prominent in untreated disease and associated with inflammatory responses and Type I IFN signaling.
  • Treatment significantly reduced the abundance and inflammatory activity of CCL19+ fibroblasts, suggesting a mechanism for halting fibrosis.
• Cell-Cell Communication: Treatment reduced signaling between NK cells and basal keratinocytes, breaking the inflammatory loop.

5. Significance

This study represents a paradigm shift in the management of LPP:

1. Mechanistic Clarity: It confirms that LPP is driven by a Type I IFN-dominant inflammatory program involving specific CD8+GZMK+ T cells and inflammatory CCL19+ fibroblasts, distinct from the CXCL13+ T-cell dominance seen in cutaneous LP.
2. Therapeutic Strategy: It validates selective TYK2 inhibition as a potent therapeutic strategy that targets both the inflammatory trigger (Type I IFN) and the fibrotic consequence (via modulation of fibroblast activity and IL-17 pathways).
3. Clinical Impact: Given the lack of approved treatments and the high rate of refractoriness in LPP, deucravacitinib offers a promising, well-tolerated option that can induce sustained remission and improve patient quality of life.
4. Future Directions: The findings support further investigation into TYK2 inhibitors for other scarring alopecias and highlight CCL19+ fibroblasts as a potential biomarker for disease activity and therapeutic response.

Note: As this is a preprint posted on medRxiv, the data has not yet undergone peer review.